Welcome to our dedicated page for ReposiTrak SEC filings (Ticker: TRAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ReposiTrak's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ReposiTrak's regulatory disclosures and financial reporting.
ReposiTrak, Inc., through its subsidiary PC Group, entered into a strategic financing arrangement with SPAR Marketing Force, Inc. via a senior unsecured promissory note of up to $4,000,000. The facility includes an initial $3,000,000 advance and an additional $1,000,000 available beginning July 17, 2026.
The note carries 8.0% annual interest, payable monthly on an interest-only basis, and matures on March 16, 2029. As part of the deal, PC Group is to receive 1,000,000 shares of SPAR Group common stock at a deemed value of $0.80 per share, with anti-dilution and price protection features.
SPAR Group, Inc. guarantees the borrower’s obligations. The agreement includes customary default triggers, after which the interest rate increases to 12.0% and PC Group can accelerate repayment.
ReposiTrak, Inc. director and CEO Randall K. Fields reported pre-planned insider sales executed by a charitable entity associated with him. RK Fields Charitable 2022, LLC sold a total of 7,500 shares of ReposiTrak common stock in open-market transactions on March 16–17, 2026 at weighted average prices slightly above $8 per share.
The filing states these sales occurred automatically under a Rule 10b5-1 trading plan adopted by Fields in his capacity as trustee of the related charitable trust to help meet charitable commitments. After these sales, that LLC held 77,500 shares. The Form 4 also shows Fields continues to hold 3,483,955 ReposiTrak common shares directly, plus additional indirect holdings through Riverview Financial Corp., his spouse, and Fields Management, Inc.
ReposiTrak, Inc. filed a current report describing the return of James R. Gillis to its Board of Directors, effective March 13, 2026. He will also serve on the Audit and Compensation Committees. The Board determined that he qualifies as an independent director under New York Stock Exchange listing standards.
Gillis is CEO of Gillis & Associates, Inc., an M&A advisory firm, and previously served on ReposiTrak’s board from 2008 to 2015. He has more than 35 years of experience in retail supply chain management, mergers and acquisitions, and organizational growth, and currently holds multiple other board and advisory roles.
ReposiTrak, Inc. director and CEO Randall K. Fields reported an indirect open-market sale of 4,000 shares of Common Stock at a weighted average price of $8.0599 per share. The shares were sold by RK Fields Charitable 2022, LLC under a pre-arranged Rule 10b5-1 trading plan established to help meet charitable commitments, with individual trade prices ranging from $7.91 to $8.17. Following the sale, that LLC holds 85,000 shares, while Fields also reports 3,483,955 shares held directly and additional indirect positions through affiliated entities and his spouse.
ReposiTrak, Inc. director and chief executive officer Randall K. Fields reported that RK Fields Charitable 2022, LLC, an entity he manages as trustee of a charitable remainder unitrust, sold 3,500 shares of common stock on March 9, 2026 at a weighted average price of $8.5612 per share.
The sale was executed automatically under a pre-established Rule 10b5-1 trading plan designed to help meet charitable commitments. After this transaction, that LLC held 89,000 shares, while Fields also reported 3,483,955 shares held directly and additional indirect holdings through Riverview Financial Corp., his spouse, and Fields Management, Inc.
ReposiTrak, Inc. reported that an entity associated with Chief Executive Officer Randall K. Fields sold a total of 7,500 shares of common stock in open‑market transactions. The sales, made by RK Fields Charitable 2022, LLC under a Rule 10b5‑1 trading plan, occurred on March 2, 3, and 4, 2026 at weighted average prices of $8.75, $8.55, and $8.6182 per share, respectively.
The trading plan was adopted by Mr. Fields in his capacity as trustee of the 2022 RK Fields Charitable Remainder Unitrust to help meet charitable commitments. After these sales, RK Fields Charitable 2022, LLC held 92,500 shares of common stock. The filing also lists additional direct and indirect holdings, including 3,483,955 common shares held directly as of March 2, 2026, along with stakes held through Riverview Financial Corp., Fields Management, Inc., and by his spouse, plus holdings of Series B Preferred Stock through Riverview Financial Corp. and his spouse.
ReposiTrak, Inc. director and chief executive officer Randall K. Fields reported indirect sales of company common stock through an affiliated charitable entity. RK Fields Charitable 2022, LLC sold 7,500 shares in open-market transactions, consisting of 5,300 shares on February 25, 2026 at a weighted average price of $8.3369 per share and 2,200 shares on February 24, 2026 at a weighted average price of $8.5026 per share. According to the disclosure, these sales occurred automatically under a pre-established Rule 10b5‑1 trading plan adopted by Fields in his capacity as trustee of a charitable remainder unitrust to help meet charitable commitments, and RK Fields Charitable 2022, LLC held 100,000 shares of ReposiTrak common stock after the transactions.
ReposiTrak, Inc. director and chief executive officer Randall K. Fields reported indirect open-market sales of the company’s common stock by an affiliated charitable entity. On February 19, 2026, RK Fields Charitable 2022, LLC sold 4,500 shares at a weighted average price of $9.0652 per share. On February 20, 2026, the same entity sold 3,000 shares at a weighted average price of $8.8238 per share under a Rule 10b5-1 trading plan adopted to help meet charitable commitments. Following these transactions, this LLC held 107,500 shares, while Fields also reported 3,483,955 shares of common stock held directly and additional indirect holdings through other related entities and his spouse, as well as indirect holdings of Series B preferred stock.
ReposiTrak, Inc. reported solid results for its fiscal second quarter ended December 31, 2025, with revenue rising 7% to $5.9 million and operating income up 34% to $1.8 million, reflecting stronger profitability. GAAP net income to common shareholders increased 13% to $1.6 million, or $0.09 per basic and diluted share, compared with $0.08 a year earlier.
The company ended the quarter with $28.7 million in cash and no bank debt, while year-to-date operating cash flow reached $3.8 million. ReposiTrak continued returning capital by paying a quarterly dividend of $0.02 per share, repurchasing about 79,927 common shares for $1.1 million, and redeeming 70,093 preferred shares for roughly $750,000.
Management highlighted growing adoption of its ReposiTrak Traceability Network and new “Touchless Traceability” technology, supported by recent patent filings. They emphasized a largely recurring SaaS revenue base, rising margins, and a strategy focused on cross-selling, continued investment in traceability solutions, and steady capital returns to shareholders.
ReposiTrak, Inc. reported higher sales and profits for the quarter and six months ended December 31, 2025 while maintaining a strong cash position and returning capital to shareholders.
Quarterly revenue rose to $5.86 million from $5.49 million, driven mainly by recurring subscription and support services across compliance, supply chain and traceability. Net income applicable to common shareholders increased to $1.64 million, with diluted earnings per share of $0.09, up from $0.08 a year earlier, helped by lower cost of services and reduced depreciation and amortization.
For the first half of fiscal 2026, revenue reached $11.83 million and net income applicable to common shareholders was $3.40 million, both above the prior-year period. The company ended the quarter with $28.7 million in cash and cash equivalents and no bank debt, and generated $3.78 million in operating cash flow over six months.
ReposiTrak continued redeeming its Series B preferred stock and repurchased common shares under its long-running buyback program, while also paying cash dividends. A quarterly dividend of $0.02 per share was declared in December 2025. Management highlights growing demand for its traceability platform as the food industry prepares for U.S. FDA FSMA 204 traceability requirements, with the compliance deadline now extended to July 20, 2028.